

Transdermal drug delivery technology

Thursday , March 10, 2005

OBJ
LIMITED

RESEARCH AND DEVELOPMENT

FOR IMMEDIATE RELEASE

UNIVERSITY TESTS CONFIRM TIME-BASED DRUG DELIVERY CAPABILITY

OBJ Limited (OBJ) is pleased to announce that independent university tests have confirmed that its drug delivery technology, Dermaportation, controls drug delivery rates up to an hour after the electronic patch technology is removed. The company believes that this is the first time a drug delivery technology has demonstrated the ability to control a rate of delivery while in place and then to selectively increase or decrease drug bioavailability up to an hour after the patch is removed.

The discovery was made as part of the second phase of the Western Australia Biomedical Research Institute (WABRI) contracted in-vitro research program for the company.

The results showed that Dermaportation was able to manage a complex drug delivery program spanning a 90 minute period, even though the Dermaportation system was active for only 30 minutes. WABRI found that OBJ's technology could influence future drug availability in a controlled manner and could double drug supply, maintain or reduce it to less than half. The ability to provide complex through-the-skin drug delivery protocols from short-term patch use may provide a new and important tool in the reduction of adverse side effects while increasing controlled release.

While the research is at an early stage, it is hoped that this new capability will allow the OBJ's development team to design the electronic patch technology to accommodate different day-time and night-time delivery protocols or to deliver different drugs at different times, during or post removal of the patch.

- ENDS -

OBJ Limited (ACN 056 482 636)

Ground Floor, 284 Oxford Street, Leederville, Western Australia 6007

Phone: +61 9 9443 3011 Fax: +61 9 9443 3866 Email: jedwards@obi.com.au

Background to the Announcement

OBJ Limited is a drug delivery company, developing electronic "drug patch" technologies that allow drugs, therapeutic agents and cosmetic compounds to be delivered more effectively and more efficiently through-the-skin.

OBJ's technology works by temporarily changing the skin's barrier effect. As this does not involve a change to the target drug or compound, new and effective delivery strategies can be created without the necessity for the drug to undergo costly re-registration. This provides pharmaceutical companies with a market friendly, cost effective and safe route of administration for many existing and newly created drugs and compounds.

The company had previously announced a 600% increase in the rate of delivery of the drug caffeine and a 70% reduction in the through-the-skin delivery times for the anaesthetic drugs lignocaine and prilocaine hydrochloride. More recently, it had demonstrated precise control over drug delivery rates and recent finding added an additional time- based control mechanism previously not seen in the drug delivery sector.

Independence of Results

OBJ contracts its drug and technology testing programs to independent and respected organisations, such as Western Australian Biomedical Research Institute or WABRI and Universities.

WABRI is a government owned and funded drug development and testing facility operated by Curtin University. The high level of independence and international accreditation means that the results by OBJ can be published and presented at major medical and scientific conferences and forums.

For more information:

Jeffrey Edwards
Phone: +61 8 944 33011
Mobile: 041 791 2211
E-mail: jedwards@obj.com.au